New hope for kids with aggressive leukemia relapse

NCT ID NCT03590171

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the drug bortezomib to standard chemotherapy helps more children with high-risk relapsed acute lymphoblastic leukemia (ALL) achieve remission. About 250 children under 18 with a first relapse of ALL will be randomly assigned to receive either standard chemo alone or chemo plus bortezomib. The goal is to improve remission rates and long-term survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Australian & New Zealand Childhood Hematology & Oncology Group

    RECRUITING

    Clayton, Victoria, 3168, Australia

  • CHU Nice

    RECRUITING

    Nice, France

  • Copenhagen University Hospital (Rigshospitalet)

    NOT_YET_RECRUITING

    Copenhagen, 2100, Denmark

  • Dpt. SCT and Hematology/Oncology University Wroclaw

    RECRUITING

    Wroclaw, 50354, Poland

  • Hòpital Universitaire des Enfants Reine Fabiola

    RECRUITING

    Brussels, 1020, Belgium

  • Instituto Português de Oncologia de Lisboa

    NOT_YET_RECRUITING

    Lisbon, Portugal

  • Oslo University Hospital

    NOT_YET_RECRUITING

    Oslo, 0027, Norway

  • Ospedale Pediatrico Bambino Gesù

    RECRUITING

    Roma, 00165, Italy

  • Prinses Máxima Centrum, Lundlaan

    RECRUITING

    Utrecht, Netherlands

  • Royal Manchester Children's Hospital

    NOT_YET_RECRUITING

    Manchester, M13 9WL, United Kingdom

  • St. Anna Kinderkrebsforschung, CCRI

    RECRUITING

    Vienna, 1090, Austria

  • Tel Aviv Sourasky Medical Centre

    RECRUITING

    Tel Aviv, 64239, Israel

  • Turku University Central Hospital

    RECRUITING

    Turku, SF-20520, Finland

  • University Hospital Motol

    RECRUITING

    Prague, Czechia

  • University Hospital Stockholm

    NOT_YET_RECRUITING

    Stockholm, 17176, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.